PG
TCRT icon

PEAK6 Group’s Alaunos Therapeutics TCRT Stock Holding History

PEAK6 Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-221
Closed -$204K – 4773
2017
Q3 		$204K Sell
221
-673
-75% -$598K ﹤0.01% 3271
2017
Q2 		$834K Buy
894
+811
+977% +$795K ﹤0.01% 2081
2017
Q1 		$79K Buy
+83
New +$77.3K ﹤0.01% 3691
2016
Q3 		– Sell
-83
Closed -$68K – 4685
2016
Q2 		$68K Sell
83
-454
-85% -$494K ﹤0.01% 3750
2016
Q1 		$597K Buy
537
+199
+59% +$204K ﹤0.01% 2125
2015
Q4 		$421K Sell
338
-117
-26% -$194K ﹤0.01% 2759
2015
Q3 		$615K Sell
455
-288
-39% -$475K ﹤0.01% 2689
2015
Q2 		$1.34M Buy
743
+555
+295% +$862K 0.01% 1817
2015
Q1 		$304K Buy
+188
New +$279K ﹤0.01% 3050

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Group's TCRT Position: Q3 2016 in Review

PEAK6 Group sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 33 shares — an estimated $27K sold.

PEAK6 Group first reported a position in TCRT in Q2 2015 and held it in 4 quarters. The position peaked at $149K in Q1 2016. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • PEAK6 Group reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • PEAK6 Group sold 33 Alaunos Therapeutics shares in Q3 2016, an estimated $27K.
  • PEAK6 Group first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 4 quarters.
  • PEAK6 Group's Alaunos Therapeutics position peaked at $149K in Q1 2016.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on PEAK6 Group's 13F filing for Q3 2016, filed 14 Nov 2016.